GCP
KERX

GSA Capital Partners’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

GSA Capital Partners’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10,300
Closed -$42K – 2080
2018
Q1 		$42K Buy
+10,300
New +$48K ﹤0.01% 1561
2016
Q2 		– Sell
-47,664
Closed -$223K – 2008
2016
Q1 		$223K Sell
47,664
-21,712
-31% -$86.7K 0.01% 1447
2015
Q4 		$350K Buy
69,376
+44,236
+176% +$210K 0.02% 1378
2015
Q3 		$88K Buy
25,140
+13,840
+122% +$92.7K ﹤0.01% 1666
2015
Q2 		$113K Sell
11,300
-52,637
-82% -$564K ﹤0.01% 1866
2015
Q1 		$814K Buy
+63,937
New +$822K 0.03% 1035
2014
Q2 		– Sell
-19,062
Closed -$325K – 2047
2014
Q1 		$325K Buy
+19,062
New +$288K 0.02% 1066
2013
Q4 		– Sell
-43,916
Closed -$444K – 1846
2013
Q3 		$444K Buy
+43,916
New +$391K 0.04% 876

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PIMJS
PKO Investment Management Joint-Stock Warsaw, Poland $1.38B AUM 59.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GSA Capital Partners's KERX Position: Q2 2018 in Review

GSA Capital Partners sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2018, closing a stake of 10,300 shares — an estimated $42K sold.

GSA Capital Partners first reported a position in KERX in Q3 2013 and held it in 8 quarters. The position peaked at $814K in Q1 2015. 132 funds tracked by Wall St. Rank hold KERX as of Q2 2018.

  • GSA Capital Partners reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2018 after selling out during the quarter.
  • GSA Capital Partners sold 10,300 Keryx Biopharmaceuticals Inc shares in Q2 2018, an estimated $42K.
  • GSA Capital Partners first reported a position in Keryx Biopharmaceuticals Inc in Q3 2013 and held it in 8 quarters.
  • GSA Capital Partners's Keryx Biopharmaceuticals Inc position peaked at $814K in Q1 2015.
  • 132 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2018.

Based on GSA Capital Partners's 13F filing for Q2 2018, filed 9 Aug 2018.